Pirtobrutinib Outperforms Bendamustine Plus Rituximab for Previously Untreated CLL/SLL

LBA-3: Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- In a new trial, the Bruton tyrosine kinase (BTK)...

Read More